清细胞细胞癌 (ccRCC) 中的Hippo通路:与VHL破坏的联系?
T Waeckel1, R Lefranc1, M Waeckel2
1Université de Caen Normandie, CNRS, Normandie Univ, ISTCT UMR6030, CYCERON, F-14000 Caen, France; Centre Hospitalier Universitaire de Caen Normandie, Service d'Urologie et Transplantation, 14000 CAEN, France.
在清细胞细胞癌 (ccRCC) 中,Hippo路径发生变化,影响瘤进展和存活率. 准Hippo-VHL轴为ccRCC患者提供了新的生物标志物和治疗方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 清细胞细胞癌 (ccRCC) 的复发率很高,缺乏可靠的生物标志物来分层患者.
- 虽然VHL基因变异是已知的驱动因素,但Hippo途径在ccRCC中的作用尚不充分探索.
研究的目的:
- 在ccRCC中审查Hippo路径的改变.
- 为了检查Hippo路径与VHL/HIF轴的交声.
- 确定潜在的ccRCC生物标志物和治疗点.
主要方法:
- 在ccRCC中对Hippo通路组件进行了全面的文献分析.
- 专注于分子机制,临床相关性和VHL信号相互作用.
主要成果:
- 河马通路的改变 (RASSF1A高甲基化,NF2突变,SAV1下调,LATS1/2无活化) 会导致ccRCC中的YAP/TAZ激活.
- 同时的3p损失会影响VHL和RASSF1,从而造成双重打击的情况.
- VHL-Hippo交叉涉及HIF诱导的信号抑制LATS1/2和YAP/TAZ促进血管生成;低RASSF1A/SAV1/LATS1/2和高YAP/TAZ与预后不佳相关.
结论:
- 河马通路是ccRCC生物学中一个关键的,被低估的因素.
- 河马路径的改变为ccRCC风险分层提供了有希望的生物标志物.
- 河马-VHL枢纽为ccRCC提供了新的治疗干预点.
更多相关视频
07:16Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
相关概念视频
Hedgehog Signaling Pathway
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Regulation of Angiogenesis and Blood Supply
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
